Role of osteoprotegerin/receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappa B ligand axis in nonalcoholic fatty liver disease.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
diabetes mellitus 2 endocrinologydiseases
hyperglycemia 1 endocrinologydiseases
obesity 15 endocrinologydiseases
osteoporosis 5 endocrinologydiseases
polycystic ovary syndrome 1 endocrinologydiseases
vascular calcification 4 endocrinologydiseases
Insulin 1 endocrinologydiseasesdrugs
glucose intolerance 1 endocrinologydiseases
hyperlipidemia 1 endocrinologydiseases
metabolic syndrome 4 endocrinologydiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Insulin 12855 metabolic complications including insulin resistance, type 2 diabetes, MetS and NAFLD.CLINICAL STUDIES Insulin resistanceNAFLD is strictly associated with IR, which is also a main determinant in the pathogenesis
Select Disease Character Offset Disease Term Instance
diabetes mellitus 14187 women with polycystic ovary syndrome. Akinci et al[[51]] found that women with a history of gestational diabetes mellitus developing MetS showed increased OPG values compared to women who did not fulfill MetS criteria. Yet,
diabetes mellitus 19267 in obese patients with MetS[[70]]. Akinci et al[[51]] found that women with a history of gestational diabetes mellitus developing the MetS showed increased OPG levels than women who did not fulfill the MetS criteria. These
glucose intolerance 1088 Patients with fatty liver display features of metabolic syndrome (MetS), like insulin resistance (IR), glucose intolerance , hypertension and dyslipidemia. Recently, epidemiological studies have linked obesity, MetS, and NAFLD
hyperglycemia 16520 a healthy population (exhibiting normal glucose tolerance and exercise stress tests, thus excluding hyperglycemia and ischemic heart disease, respectively), Ashley et al[[58]] found that OPG correlated inversely with
hyperlipidemia 3904 with metabolic syndrome (MetS), including insulin resistance (IR), chronic systemic inflammation and hyperlipidemia . Recently, epidemiological studies have linked obesity, MetS, and NAFLD to decreased bone mineral density
metabolic syndrome 1031 of chronic liver disease in both adults and children. Patients with fatty liver display features of metabolic syndrome (MetS), like insulin resistance (IR), glucose intolerance, hypertension and dyslipidemia. Recently,
metabolic syndrome 2244 underlying mechanisms linking OPG and NAFLD.Core tip: Recently, epidemiological studies have linked obesity, metabolic syndrome , and nonalcoholic fatty liver disease (NAFLD) to decreased bone mineral density and osteoporosis, highlighting
metabolic syndrome 3808 disease[[7]-[11]]. These diseases have the same underlying pathophysiological features associated with metabolic syndrome (MetS), including insulin resistance (IR), chronic systemic inflammation and hyperlipidemia. Recently,
metabolic syndrome 24564 patients.Monseu et al[[80]], 2016Cross-sectional study314 adult subjects with at least one criterion for metabolic syndrome .OPG levels were positively associated with both liver markers (such as alanine aminotransferase, gamma-glutamyl
obesity 845 5/2018Publication date (epub): 5/2018AbstractConcomitantly with the increase in the prevalences of overweight/ obesity , nonalcoholic fatty liver disease (NAFLD) has worldwide become the main cause of chronic liver disease
obesity 1186 (IR), glucose intolerance, hypertension and dyslipidemia. Recently, epidemiological studies have linked obesity , MetS, and NAFLD to decreased bone mineral density and osteoporosis, highlighting an intricate interplay
obesity 1623 for its role in bone metabolism, may also play critical roles in the initiation and perpetuation of obesity -related comorbidities. Clinical data have indicated that OPG concentrations are associated with hypertension,
obesity 2235 underlying mechanisms linking OPG and NAFLD.Core tip: Recently, epidemiological studies have linked obesity , metabolic syndrome, and nonalcoholic fatty liver disease (NAFLD) to decreased bone mineral density
obesity 2687 activation, has recently been suggested to have critical roles in the initiation and perpetuation of obesity -related comorbidities including NAFLD. The available studies have reported either positive or negative
obesity 2983 in this liver disease.INTRODUCTIONConcomitantly with the increase in the prevalences of overweight/ obesity , nonalcoholic fatty liver disease (NAFLD) has worldwide become the main cause of chronic liver disease
obesity 3966 (IR), chronic systemic inflammation and hyperlipidemia. Recently, epidemiological studies have linked obesity , MetS, and NAFLD to decreased bone mineral density (BMD) and osteoporosis, highlighting an intricate
obesity 5165 bone resorption in osteoporosis, may also play critical roles in the initiation and perpetuation of obesity -related comorbidities[[21]-[23]]. There is arising evidence that RANKL/RANK/OPG system participate in
obesity 13511 association between OPG and IR with contrastant results[[48]-[62]]. In a cohort of 106 subjects with obesity , including eighteen with type 2 diabetes, Gannage-Yared et al[[48]] demonstrated a positive relationship
obesity 17479 Ayina et al[[62]] demonstrated that HOMA-IR was inversely associated with OPG values in women with obesity , meaning that elevated OPG concentrations may be expression of high insulin sensitivity.The heterogeneity
obesity 18462 homeostasis[[66]] and recently shown to involve insulin actions[[67]]. OPG concentrations in patients affected by obesity and type 2 diabetes may thus reflect the presence of CVD.Metabolic syndromeScant and contrastant literature
obesity 19564 women with previous gestational diabetes and 67 age-matched controls. OPG values were associated with obesity , IR, and carotid IMT[[71]].Recently, Pérez de Ciriza et al[[72]] demonstrated that patients with MetS
obesity 22379 higher risk for NAFLD. Finally, Erol et al[[78]] evaluated the association of OPG concentrations with obesity , IR, and NAFLD in children and adolescents. OPG concentrations in the youth with obesity were significantly
obesity 22468 concentrations with obesity, IR, and NAFLD in children and adolescents. OPG concentrations in the youth with obesity were significantly decreased than in controls. Among obese youths, those with high fasting insulin and
obesity 25194 for NAFLD (OR = 3.49, 95%CI: 1.86-6.94).Erol et al[[78]], 2016Cross-sectional study107 children with obesity of whom 62 had ultrasound-proven NAFLD and 37 control subjects.OPG levels in the obese group were significantly
osteoporosis 1249 epidemiological studies have linked obesity, MetS, and NAFLD to decreased bone mineral density and osteoporosis , highlighting an intricate interplay among bone, adipose tissue, and liver. Osteoprotegerin (OPG), an
osteoporosis 2347 metabolic syndrome, and nonalcoholic fatty liver disease (NAFLD) to decreased bone mineral density and osteoporosis , highlighting an intricate interplay among bone, adipose tissue, and liver. Osteoprotegerin (OPG), an
osteoporosis 4035 epidemiological studies have linked obesity, MetS, and NAFLD to decreased bone mineral density (BMD) and osteoporosis , highlighting an intricate interplay among bone, adipose tissue, and liver[[12]-[14]]. With regard to
osteoporosis 5084 (IL)-1b, IL-6, and TNF-α] that are regulated by the RANKL-OPG axis in mediating bone resorption in osteoporosis , may also play critical roles in the initiation and perpetuation of obesity-related comorbidities[[21]-[23]].
osteoporosis 15666 et al[[56]] showed that OPG values were significantly increased in postmenopausal women affected by osteoporosis and impaired glucose metabolism (including impaired glucose tolerance and type 2 diabetes) than women
polycystic ovary syndrome 14094 population. Pepene et al[[50]] reported a positive association of OPG with HOMA-IR in a cohort of women with polycystic ovary syndrome . Akinci et al[[51]] found that women with a history of gestational diabetes mellitus developing MetS
vascular calcification 1771 have indicated that OPG concentrations are associated with hypertension, left ventricular hypertrophy, vascular calcification , endothelial dysfunction, and severity of liver damage in chronic hepatitis C. Nonetheless, the relationship
vascular calcification 5657 concentrations are associated with hypertension and left ventricular hypertrophy in the general population, with vascular calcification and altered endothelial function in subjects with and without diabetes, and with severity of liver damage
vascular calcification 18262 strong, independent predictor of CVD[[63],[64]]. In particular, plasma OPG is considered a marker of vascular calcification s[[65]], a feature often seen in patients with impaired glucose homeostasis[[66]] and recently shown
vascular calcification 29548 associated positively with severity and progression of coronary artery disease, atherosclerosis, and vascular calcification whereas animal studies support a protective role for OPG[[87]]. Future studies are necessary to clarify

You must be authorized to submit a review.